{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T21:20:50Z","timestamp":1786483250215,"version":"build-2736575974"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI23-01646, CD25\/00046"],"award-info":[{"award-number":["PI23-01646, CD25\/00046"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["RYC2021-030875-I"],"award-info":[{"award-number":["RYC2021-030875-I"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Peripheral immune biomarkers provide a minimally invasive approach to monitor systemic responses to cancer immunotherapy, yet their predictive value in real-world longitudinal settings remains incompletely defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a prospective longitudinal study in patients with advanced melanoma and non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors. Thirteen circulating immune, inflammatory, and nutritional biomarkers were analyzed across treatment cycles, and their association with radiological response over time was assessed using Bayesian ordinal mixed-effects models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nine biomarkers showed significant longitudinal associations with clinical outcomes. CD4+ T cells emerged as the strongest predictor of favorable response, followed by CD3+ and CD45+ T cells, natural killer cells, albumin, and total protein, whereas elevated neutrophils, lactate dehydrogenase, and the neutrophil-to-lymphocyte ratio were associated with poor outcomes. No significant effects were observed for CD8+ T cells, B cells, total lymphocytes, or the CD4\/CD8 ratio.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These findings identify circulating CD4+ T cells as the most informative peripheral biomarker associated with longitudinal response to immune checkpoint inhibitors and support the clinical utility of peripheral immune profiling as a dynamic, minimally invasive strategy for monitoring treatment efficacy in routine oncology practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1854351","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:35:44Z","timestamp":1783575344000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Circulating immune and biochemical markers predict tumor response to immunotherapy in advanced melanoma and lung cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Silvia","family":"Sequero-Lopez","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario San Cecilio","place":["Granada, Spain"]},{"name":"Faculty of Medicine, University of M\u00e1laga","place":["M\u00e1laga, Spain"]},{"name":"IBS Granada, Instituto de Investigaci\u00f3n Biosanitaria de Granada","place":["Granada, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Castillo-Barnes","sequence":"additional","affiliation":[{"name":"Communications Engineering, University of M\u00e1laga","place":["M\u00e1laga, Spain"]},{"name":"IBIMA Plataforma Bionand, Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga","place":["M\u00e1laga, Spain"]},{"name":"Instituto Andaluz Interuniversitario en Ciencia de Datos e Inteligencia Computacional (DaSCI)","place":["Granada, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"G\u00e1lvez-Carvajal","sequence":"additional","affiliation":[{"name":"IBIMA Plataforma Bionand, Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga","place":["M\u00e1laga, Spain"]},{"name":"Department of Medical Oncology, Hospital Universitario Virgen de la Victoria","place":["M\u00e1laga, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Palaz\u00f3n-Carri\u00f3n","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario Virgen de la Macarena","place":["Seville, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Jes\u00fas","family":"Mart\u00ednez-Murcia","sequence":"additional","affiliation":[{"name":"Instituto Andaluz Interuniversitario en Ciencia de Datos e Inteligencia Computacional (DaSCI)","place":["Granada, Spain"]},{"name":"Signal Theory, Networking and Communications, University of Granada","place":["Granada, Spain"]},{"name":"Centro de Investigaci\u00f3n en Tecnolog\u00edas de la Informaci\u00f3n y las Comunicaciones (CITIC-UGR)","place":["Granada, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"de la Cruz-Merino","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario Virgen de la Macarena","place":["Seville, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Mu\u00f1oz-Couselo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario Vall d\u2019Hebron","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Provencio","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario Puerta de Hierro-Majadahonda","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Ortiz","sequence":"additional","affiliation":[{"name":"Communications Engineering, University of M\u00e1laga","place":["M\u00e1laga, Spain"]},{"name":"Instituto Andaluz Interuniversitario en Ciencia de Datos e Inteligencia Computacional (DaSCI)","place":["Granada, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"G\u00f3rriz","sequence":"additional","affiliation":[{"name":"Instituto Andaluz Interuniversitario en Ciencia de Datos e Inteligencia Computacional (DaSCI)","place":["Granada, Spain"]},{"name":"Signal Theory, Networking and Communications, University of Granada","place":["Granada, Spain"]},{"name":"Centro de Investigaci\u00f3n en Tecnolog\u00edas de la Informaci\u00f3n y las Comunicaciones (CITIC-UGR)","place":["Granada, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Ram\u00edrez","sequence":"additional","affiliation":[{"name":"Instituto Andaluz Interuniversitario en Ciencia de Datos e Inteligencia Computacional (DaSCI)","place":["Granada, Spain"]},{"name":"Signal Theory, Networking and Communications, University of Granada","place":["Granada, Spain"]},{"name":"Centro de Investigaci\u00f3n en Tecnolog\u00edas de la Informaci\u00f3n y las Comunicaciones (CITIC-UGR)","place":["Granada, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rueda-Dom\u00ednguez","sequence":"additional","affiliation":[{"name":"IBIMA Plataforma Bionand, Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga","place":["M\u00e1laga, Spain"]},{"name":"Department of Medical Oncology, Hospital Universitario Virgen de la Victoria","place":["M\u00e1laga, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Blancas","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario San Cecilio","place":["Granada, Spain"]},{"name":"IBS Granada, Instituto de Investigaci\u00f3n Biosanitaria de Granada","place":["Granada, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41417-020-0183-x","article-title":"Revisiting the role of CD4+ T cells in cancer immunotherapy: new insights into old paradigms","volume":"28","author":"Tay","year":"2020","journal-title":"Cancer Gene Ther"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1158\/2326-6066.cir-22-0952","article-title":"Cancer immunology research: a decade of illumination and innovation","volume":"11","author":"Schreiber","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-24-0979","article-title":"Tertiary lymphoid structures are associated with enhanced macrophage activation and immune checkpoint expression and predict outcome in cervical cancer","volume":"13","author":"Gorvel","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-19-0574","article-title":"CD4+ T-cell immunity in the peripheral blood correlates with response to anti-PD-1 therapy","volume":"8","author":"Kagamu","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.1039121","article-title":"The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"9","author":"Guven","year":"2022","journal-title":"Front Mol Biosci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2021.734735","article-title":"Hypoalbuminaemia as a prognostic biomarker of first-line treatment resistance in metastatic non-small cell lung cancer","volume":"8","author":"Stares","year":"2021","journal-title":"Front Nutr"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01048-4","article-title":"Cytotoxic CD8+ T cells in cancer and cancer immunotherapy","volume":"124","author":"Raskov","year":"2020","journal-title":"Br J Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0044-0","article-title":"CD4+ T cell help in cancer immunology and immunotherapy","volume":"18","author":"Borst","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.12.011","article-title":"B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma","volume":"35","author":"Gavrielatou","year":"2024","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01145-x","article-title":"Development of NK cell-based cancer immunotherapies through receptor engineering","volume":"21","author":"Page","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06199-x","article-title":"CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours","volume":"618","author":"Kruse","year":"2023","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00889-12","article-title":"Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection","volume":"86","author":"Angelosanto","year":"2012","journal-title":"J Virol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.cell.2018.11.043","article-title":"Dysfunctional CD8 T cells form a proliferative, dynamically regulated compartment within human melanoma","volume":"176","author":"Li","year":"2019","journal-title":"Cell"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u226550%","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.004","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.09.022","article-title":"Atezolizumab versus docetaxel in pretreated patients with NSCLC: final results from the randomized phase 2 POPLAR and phase 3 OAK clinical trials","volume":"16","author":"Mazieres","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ejca.2022.08.029","article-title":"Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: prevalence and impact on patients\u2019 health-related quality of life","volume":"176","author":"Schulz","year":"2022","journal-title":"Eur J Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03541-0","article-title":"Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition","volume":"72","author":"van Eijs","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B27","doi-asserted-by":"publisher","first-page":"S999","DOI":"10.1016\/j.annonc.2021.08.1889","article-title":"Immune T-cell subpopulations from the peripheral blood of non-small cell lung cancer patients are associated with the efficacy of anti-PD-1 immunotherapy","volume":"32","author":"Rogado","year":"2021","journal-title":"Ann Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216318","article-title":"The opportunities and challenges in immunotherapy: insights from the regulation of PD-L1 in cancer cells","volume":"569","author":"Lin","year":"2023","journal-title":"Cancer Lett"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/bs.ircmb.2018.08.001","article-title":"Cancer immunosurveillance by T cells","volume":"342","author":"Rao","year":"2019","journal-title":"Int Rev Cell Mol Biol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-020-01817-1","article-title":"Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review","volume":"18","author":"Cupp","year":"2020","journal-title":"BMC Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-24-378","article-title":"The prognostic role of albumin levels in lung cancer patients receiving advanced immunotherapy","volume":"13","author":"Chen","year":"2024","journal-title":"Transl Lung Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005670","article-title":"Serum albumin: a pharmacokinetic marker for optimizing treatment outcome of immune checkpoint blockade","volume":"10","author":"Zheng","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"B34","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4419-0300-6","volume-title":"Linear Mixed Models for Longitudinal Data","author":"Molenberghs","year":"2000"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.7717\/peerj-cs.1516","article-title":"PyMC: a modern probabilistic programming framework in Python","volume":"9","author":"Abril-Pla","year":"2023","journal-title":"PeerJ Comput Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00521-2","article-title":"CD4+ T cells in cancer","volume":"4","author":"Speiser","year":"2023","journal-title":"Nat Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.867","article-title":"Induction of connective tissue growth factor accounts for glucocorticoid suppression failure in pulmonary fibrosis","volume":"12","author":"Wang","year":"2022","journal-title":"Clin Transl Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmeth.2023.100546","article-title":"A topic modeling approach reveals dynamic T cell composition during immunotherapy","volume":"3","author":"Peng","year":"2023","journal-title":"Cell Rep Methods"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2023.100396","article-title":"Supervised clustering of peripheral immune cells associated with response to checkpoint inhibitors","volume":"20","author":"Kverneland","year":"2023","journal-title":"Immuno Oncol Technol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-20-0637","article-title":"Longitudinal immune profiling reveals unique myeloid and T-cell phenotypes","volume":"9","author":"Ager","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-0272-z","article-title":"The cancer\u2013natural killer cell immunity cycle","volume":"20","author":"Huntington","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.coi.2021.09.005","article-title":"The role of CD4 T cells in rejection of solid tumors","volume":"74","author":"Poncette","year":"2022","journal-title":"Curr Opin Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1482807","article-title":"The innate defenders: a review of natural killer cell immunotherapies in cancer","volume":"15","author":"\u00c1lvarez-Carrasco","year":"2024","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-025-01297-4","article-title":"Adjusting the scope of natural killer cells in cancer therapy","volume":"22","author":"Shen","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-025-03375-x","article-title":"Natural killer cells: the immune frontline against circulating tumor cells","volume":"44","author":"Masmoudi","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-24-0561","article-title":"Inflammatory stress determines treatment need in HER2-positive esophagogastric cancer","volume":"13","author":"Tintelnot","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-23-0642","article-title":"Functional reprogramming of neutrophils in colitis-associated cancer","volume":"12","author":"Ghosh","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6074.tumimm24-a007","article-title":"Prognostic significance of blood counts and tumor-infiltrating lymphocytes in NSCLC","volume":"12","author":"Tostes","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105575","article-title":"Profiling autoantibodies during immune checkpoint inhibitor therapy in renal cell carcinoma","volume":"10","author":"Fritzsch","year":"2025","journal-title":"ESMO Open"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01187-y","article-title":"Neutrophils in cancer carcinogenesis and metastasis","volume":"14","author":"Xiong","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2022.13552","article-title":"Low serum albumin levels and high neutrophil counts predict poorer prognosis","volume":"24","author":"Xiang","year":"2022","journal-title":"Oncol Lett"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1721090","article-title":"Mechanistic roles of neutrophil heterogeneity in tumour pathogenesis","volume":"16","author":"Lin","year":"2025","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1323192","article-title":"Predictive value of serum albumin levels on cancer survival","volume":"14","author":"Tang","year":"2024","journal-title":"Front Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s13045-025-01722-1","article-title":"Application of single-cell omics in cancer drug response and resistance","volume":"18","author":"Cheng","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2025.2602806","article-title":"Pretreatment hyperferritinaemia as an independent prognostic marker in metastatic solid tumors treated with immune checkpoint inhibitors","volume":"26","author":"A\u00e7ar","year":"2025","journal-title":"Expert Rev Anticancer Ther"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-025-04024-7","article-title":"Dynamic blood-based biomarkers predict early response to ipilimumab and nivolumab in advanced melanoma","volume":"28","author":"\u015eahin","year":"2026","journal-title":"Clin Transl Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1854351\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:35:46Z","timestamp":1783575346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1854351\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":56,"alternative-id":["10.3389\/fimmu.2026.1854351"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1854351","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"article-number":"1854351"}}